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7 Abstract
8 V&egran and colleagues proposed a model in which the lactate released from tumor cells through MCT4 would
9 be taken up by endothelial cells via theMCT1 transporter and stimulate angiogenesis, using human umbilical vein
10 endothelial cell (HUVEC) as model of tumor endothelial cells. By analyzing a total of 505 cases of human tumor
11 samples immunostained for MCT1, we do not conﬁrm plasma membrane expression of MCT1 in the endothelial
12 cells of tumor-associated vessels. Cancer Res; 72(00); 1–2. !2012 AACR.
13
14
15
16 We read with great interest the work of V&egran and collea-
17 gues published recently (1), where the authors nicely showed,
18 using human umbilical vein endothelial cell (HUVEC) as a
19 model, that lactate induces angiogenesis through NF-kB/
20 interleukin-8 (IL-8) signaling. The entrance of lactate in endo-
21 thelial cells was shown to be mediated by monocarboxylate
22 transporter MCT1, present in HUVECs. The authors then
23 proposed a model in which the lactate released from tumor
25cells through MCT4 would be taken up by endothelial cells via
26the MCT1 transporter and stimulate angiogenesis.
27Our group has been studying the expression of MCT1 and
28MCT4 in several human tumor samples, including colorectal
29(2), uterine cervix (3), and breast (4), in a total of 505 cases. In
30the light of the results presented by V&egran and colleagues, we
31checked again all our samples and we did not ﬁnd any clear
32MCT1 plasma membrane expression in endothelial cells of
33blood vessels in any of the tumor samples. Representative
34pictures of MCT1 immunohistochemistry in the different
35tumors are shown in Fig. 1, in which negative reactions can
36be seen in the endothelial cells of blood vessels near tumor
37cells. We conﬁrmed the speciﬁcity of the MCT1 antibody we
38used for immunohistochemistry, by Western blotting (2) and,
39most recently, by siRNA (unpublished results), which is the
40same as the authors used in the present article.
41Even though HUVECs have been largely used as an in vitro
42model for tumor angiogenesis, they are isolated from the vein
43of the umbilical cord and there are evident differences in gene
44expression between their phenotype and tumor endothelial
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Figure 1. Representative
immunoreactions for MCT1 in
cervical (A, D), colorectal
(B, E), and breast cancer (C, F),
where negative staining of
endothelial cells in the vicinity
of tumor cells can be seen
(black arrowheads). A–C, !200
magniﬁcation; D–F, !400
magniﬁcation.
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47 cells (5), which may also be the case of MCT1. Indeed, by using
48 the same technique, antibody and specimen processing, we see
49 clear expression of MCT1 in HUVECs (Fig. 2) but do not
50 conﬁrm plasma membrane expression of MCT1 in tumor-
51 associated vessels.
52 Wewould like to leave themessage that one should interpret
53 the results from studies using in vitro models with caution, as
54 they might not reﬂect accurately what happens in human
55 tissues.
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Figure 2. Representative
immunoreactions for MCT1 in
HUVECs (A) and umbilical cord (B),
where positive staining for MCT1
can be seen (black arrowhead).
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